Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SI-BONE is a medical device company specializing in minimally invasive surgical implants for sacroiliac joint fusion, primarily its iFuse Implant System. The company targets the estimated 15-20% of chronic lower back pain cases attributable to SI joint dysfunction, competing against traditional open surgery and conservative pain management. Revenue growth is driven by procedure volume expansion, surgeon training, and increasing insurance coverage for the iFuse procedure.
SI-BONE sells single-use implant kits (typically 3-4 implants per procedure at $3,000-5,000 per kit) directly to hospitals and ambulatory surgery centers. Revenue scales with procedure volume growth, which depends on: (1) expanding surgeon adoption through training programs and clinical evidence, (2) securing favorable reimbursement from Medicare and commercial payers, and (3) converting patients from conservative treatment or open fusion. The 79% gross margin reflects manufacturing scale on proprietary titanium implants with minimal direct competition. Operating losses stem from heavy commercial infrastructure (100+ sales reps) and ongoing clinical trial investments to expand indications and payer coverage.
Quarterly procedure volume growth rates and guidance - market expects 18-22% annual growth to justify valuation
Medicare coverage decisions and commercial payer policy updates for SI joint fusion (CPT code 27279)
Clinical trial readouts for expanded indications (degenerative sacroiliitis, adjacent segment disease post-lumbar fusion)
Sales force productivity metrics - procedures per rep, new surgeon training completions
Gross margin trajectory as manufacturing scales and product mix shifts toward higher-margin international sales
Reimbursement policy risk - Medicare or commercial payers could restrict coverage criteria, require additional clinical evidence, or reduce payment rates for SI joint fusion procedures, directly impacting procedure economics and adoption
Clinical evidence challenges - failure to demonstrate superiority over conservative treatment or fusion alternatives in ongoing trials could limit market expansion and trigger payer coverage reversals
Regulatory pathway for competitors - FDA 510(k) clearance for competing SI joint implants is relatively accessible, lowering barriers to entry as the market validates
Emerging competition from Medtronic, Stryker, and Zyga Technology (acquired by Zimmer Biomet) entering SI joint fusion market with established orthopedic sales forces and hospital relationships
Substitution risk from radiofrequency ablation and other minimally invasive pain management techniques that avoid implant costs and surgical risks
Surgeon loyalty fragmentation as multiple implant options become available, potentially commoditizing the procedure and pressuring ASPs
Cash burn sustainability - with negative $15M annual FCF and $100M+ cash position, the company has 6-7 years of runway at current burn, but accelerated losses or slower growth could necessitate dilutive equity raises
Working capital management - rapid growth strains inventory and receivables, and any deterioration in DSO or inventory turns would accelerate cash consumption
moderate - Elective orthopedic procedures exhibit cyclical sensitivity as patients defer non-urgent surgeries during economic uncertainty or when out-of-pocket costs rise. However, SI joint fusion addresses chronic pain (average 5+ years of symptoms), creating pent-up demand that partially insulates volumes. Hospital capital budgets and ASC procedure scheduling are more sensitive to GDP and employment trends than emergency care. Estimate 60-70% correlation with broader elective surgery volumes.
Rising rates pressure valuation multiples for unprofitable growth companies, as SI-BONE's negative FCF makes it sensitive to discount rate changes. Higher rates also increase financing costs for hospitals and ASCs, potentially delaying capital equipment purchases or tightening procedure approval processes. Patient financing for out-of-pocket costs becomes more expensive, though SI joint fusion typically has lower patient cost-sharing than spinal fusion alternatives. Primary impact is multiple compression rather than fundamental demand destruction.
Minimal direct credit exposure. SI-BONE sells to hospitals and ASCs with established payment cycles (60-90 days), and bad debt is negligible given institutional customers. The company maintains a strong balance sheet (7.97x current ratio, 0.21 debt/equity) with limited refinancing risk. Indirect exposure exists if credit tightening reduces hospital capital availability or payer reimbursement delays, but this is secondary to procedure volume drivers.
growth - Investors focus on revenue CAGR (20%+ required), market penetration in underpenetrated SI joint dysfunction diagnosis (estimated <5% of addressable patients currently treated surgically), and path to profitability by 2027-2028. The stock attracts growth-at-reasonable-price investors given 3.4x P/S vs. 5-8x for high-growth medtech peers, but requires conviction in clinical evidence and reimbursement sustainability. Not suitable for value or income investors given negative earnings and no dividend.
high - Small-cap medtech with binary catalysts (reimbursement decisions, clinical trial readouts) and illiquid float ($700M market cap) creates 40-50% annualized volatility. Stock exhibits 20-30% single-day moves on coverage policy announcements or earnings surprises. Beta estimated at 1.3-1.5x vs. healthcare sector, with additional idiosyncratic risk from single-product concentration.
